カテゴリー： Grand View Research, 世界

医薬品の副作用調査の世界市場分析：臨床試験フェーズ別（前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験）、サービス提供者別（自宅内、契約委託）、セグメント予測、-2020

【英語タイトル】Pharmacovigilance Market Analysis By Clinical Trial Phases (Preclinical Studies, Phase I/1, Phase II/2, Phase III/3, Phase IV/4 Trial), By Type Of Service Providers (In House, Contract Outsourcing) And Segment Forecasts To 2020

Grand View Researchが出版した調査資料（GVIEW707656）・商品コード：GVIEW707656
・発行会社（調査会社）：Grand View Research
・発行日：2015年2月15日
・ページ数：102
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール
・調査対象地域：グローバル
・産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD4,700 ⇒換算￥507,600見積依頼/購入/質問フォーム
Multi UserUSD8,000 ⇒換算￥864,000見積依頼/購入/質問フォーム
Global/corporate LicenseUSD10,500 ⇒換算￥1,134,000見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
本調査レポートでは、医薬品の副作用調査の世界市場について調査・分析し、医薬品の副作用調査の世界市場動向、医薬品の副作用調査の世界市場規模、市場予測、セグメント別医薬品の副作用調査市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。
【レポートの概要】

Global pharmacovigilance market is expected to reach USD 5.51 billion by 2020. Increasing incidence rates of adverse drug reaction and the introduction of stringent drug safety regulations are some key drivers of this market. ADR is responsible for approximately 5% of the hospitalization in developed countries annually, and this is expected to boost usage rates over the next six years. Pharmacovigilance has witnessed a significant rise in usage rates in the recent times owing to growing global geriatric population triggering a growth in demand for new drug development. Additionally, health regulatory authorities such as the U.S. FDA and EMEA (European Medicines Agency) are now emphasizing on electronic submission of data which is also expected to drive the pharmacovigilance market.
Contract outsourcing pharmacovigilance market is expected to grow at a lucrative rate of over 13.1% during the forecast period. Service flexibility and cost effectiveness associated with outsourcing are some key factors accounting for the segment’s lucrative growth.

Further key findings from the study suggest:

Pharmacovigilance services found the largest application in phase 4/IV clinical trial studies in 2013. Greater applicability and relevance are some factors accounting for the segment’s market position.
Contract outsourcing was the most revenue generating service provider segment in 2013. Minimization of upfront investments and reduction in fixed overhead costs are some factors expected to drive segment growth.
North America was the largest regional market, accounting for over 40.0% of the revenue in 2013. Presence of stringent healthcare regulations implemented by the U.S. FDA and high market penetration rates of electronic medical records are some factors responsible for its large share.
Asia Pacific is identified as the most lucrative market. Presence of a large pool of skilled labor and favorable business environments are some factors expected to drive regional market growth. Rapidly improving healthcare infrastructure in the emerging economies of India and China is also expected to provide new growth opportunities to the market participants.
Key players of this market include Quintiles Transnational Corporation, PAREXEL International, Clinquest Group BV, Pharmaceutical Product Development, Accenture Plc., Boehringer Ingelheim GmbH and Cognizant Technology Solutions
Providing customized end to end PV solutions & services and entering into strategic agreements are some key strategies adopted by these market players.
For the purpose of this study, Grand View Research has segmented the pharmacovigilance market on the basis of clinical trial phase, type of service provider and region:

Global Pharmacovigilance Clinical Trial Phase Outlook (Revenue, USD Million, 2012 – 2020)
• Pre Clinical
• Phase 0
• Phase 1/I
• Phase 2/II
• Phase 3/III
• Phase 4/IV
Global Pharmacovigilance Service Provider Outlook (Revenue, USD Million, 2012 – 2020)
• In- House
• Contract Outsourcing
Pharmacovigilance Regional Outlook (Revenue, USD Million, 2012 – 2020)
• North America
• Europe
• Asia Pacific
• RoW

【レポートの目次】

Table of Contents

Chapter 1. Executive Summary
1.1. Pharmacovigilance– Industry Summary and Critical Success Factors (CSFs)
Chapter 2. Pharmacovigilance Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. Pharmacovigilance – Market dynamics
2.3.1. Market Driver Analysis
2.3.2. Market Restraint Analysis
2.4. Key Opportunities Prioritized
2.5. Pharmacovigilance – PESTEL Analysis
2.6. Pharmacovigilance Company Market Share Analysis, 2013
Chapter 3. Pharmacovigilance Clinical Trial Phase Outlook
3.1. Pharmacovigilance market share, by clinical trial phase, 2013 & 2020
3.2. Preclinical
3.2.1. Preclinical Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.3. Phase 0
3.3.1. Phase 0 Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.4. Phase I
3.4.1. Phase I Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.5. Phase II
3.5.1. Phase II Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.6. Phase III
3.6.1. Phase III Market Estimates and Forecasts, 2012 – 2020 (USD Million)
3.7. Phase IV
3.7.1. Phase IV Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 4. Pharmacovigilance Type of Service Provider Outlook
4.1. Pharmacovigilance market share, by type of service provider, 2013 & 2020
4.2. In- House
4.2.1. In-House Market Estimates and Forecasts, 2012 – 2020 (USD Million)
4.3. Contract Outsourcing
4.3.1. Contract Outsourcing Market Estimates and Forecasts, 2012 – 2020 (USD Million)
Chapter 5. Pharmacovigilance Regional Outlook
5.1. Pharmacovigilance market share by region, 2012 & 2020
5.2. North America
5.2.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.2.2. Market Estimates and Forecasts, by Type of Service Provider
5.3. Europe
5.3.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.3.2. Market Estimates and Forecasts, by Type of Service Provider
5.4. Asia Pacific
5.4.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.4.2. Market Estimates and Forecasts, by Type of Service Provider
5.5. RoW
5.5.1. Market Estimates and Forecasts, by Clinical Trial Phase
5.5.2. Market Estimates and Forecasts, by Type of Service Provider
Chapter 6. Competitive Landscape
6.1 Accenture Plc.
6.1.1 Company Overview
6.1.2 Financial Performance
6.1.3 Product Benchmarking
6.1.4 Strategic Initiatives
6.2 Boehringer Ingelheim GmbH
6.2.1 Company Overview
6.2.2 Financial Performance
6.2.3 Product Benchmarking
6.2.4 Strategic Initiatives
6.3 Bristol-Myers Squibb
6.3.1 Company Overview
6.3.2 Financial Performance
6.3.3 Product Benchmarking
6.3.4 Strategic Initiatives
6.4 Clinquest Group B.V.
6.4.1 Company Overview
6.4.2 Financial Performance
6.4.3 Product Benchmarking
6.4.4 Strategic Initiatives
6.5 Cognizant Technology Solutions Corporation
6.5.1 Company Overview
6.5.2 Financial Performance
6.5.3 Product Benchmarking
6.5.4 Strategic Initiatives
6.6 Covance, Inc.
6.6.1 Company Overview
6.6.2 Financial Performance
6.6.3 Product Benchmarking
6.6.4 Strategic Initiatives
6.7 F. Hoffmann-La Roche Ltd
6.7.1 Company Overview
6.7.2 Financial Performance
6.7.3 Product Benchmarking
6.7.4 Strategic Initiatives
6.8 GlaxoSmithKline (GSK)
6.8.1 Company Overview
6.8.2 Financial Performance
6.8.3 Product Benchmarking
6.8.4 Strategic Initiatives
6.9 IBM Corporation
6.9.1 Company Overview
6.9.2 Financial Performance
6.9.3 Product Benchmarking
6.9.4 Strategic Initiatives
6.10 ICON, Plc
6.10.1 Company Overview
6.10.2 Financial Performance
6.10.3 Product Benchmarking
6.10.4 Strategic Initiatives
6.11 iGATE Corporation
6.11.1 Company Overview
6.11.2 Financial Performance
6.11.3 Product Benchmarking
6.11.4 Strategic Initiatives
6.12 iMEDGlobal Corporation
6.12.1 Company Overview
6.12.2 Financial Performance
6.12.3 Product Benchmarking
6.12.4 Strategic Initiatives
6.13 Infosys
6.13.1 Company Overview
6.13.2 Financial Performance
6.13.3 Product Benchmarking
6.13.4 Strategic Initiatives
6.14 Ipca Laboratories Ltd
6.14.1 Company Overview
6.14.2 Financial Performance
6.14.3 Product Benchmarking
6.14.4 Strategic Initiatives
6.15 Janssen Research & Development, LLC
6.15.1 Company Overview
6.15.2 Financial Performance
6.15.3 Product Benchmarking
6.15.4 Strategic Initiatives
6.16 Novartis International AG
6.16.1 Company Overview
6.16.2 Financial Performance
6.16.3 Product Benchmarking
6.16.4 Strategic Initiatives
6.17 PAREXEL International Corporation
6.17.1 Company Overview
6.17.2 Financial Performance
6.17.3 Product Benchmarking
6.17.4 Strategic Initiatives
6.18 Pfizer, Inc.
6.18.1 Company Overview
6.18.2 Financial Performance
6.18.3 Product Benchmarking
6.18.4 Strategic Initiatives
6.19 Pharmaceutical Product Development, Inc. (PPD, Inc.)
6.19.1 Company Overview
6.19.2 Financial Performance
6.19.3 Product Benchmarking
6.19.4 Strategic Initiatives
6.20 Sanofi Aventis
6.20.1 Company Overview
6.20.2 Financial Performance
6.20.3 Product Benchmarking
6.20.4 Strategic Initiatives
6.21 Synowlwedge LLC
6.21.1 Company Overview
6.21.2 Financial Performance
6.21.3 Product Benchmarking
6.21.4 Strategic Initiatives
6.22 Wipro Ltd.
6.22.1 Company Overview
6.22.2 Financial Performance
6.22.3 Product Benchmarking
6.22.4 Strategic Initiatives
6.23 PRA Health Sciences Inc.
6.23.1 Company Overview
6.23.2 Financial Performance
6.23.3 Product Benchmarking
6.23.4 Strategic Initiatives
6.24 Quantum Solutions India
6.24.1 Company Overview
6.24.2 Financial Performance
6.24.3 Product Benchmarking
6.24.4 Strategic Initiatives
6.25 Quintiles Transnational Corporation
6.25.1 Company Overview
6.25.2 Financial Performance
6.25.3 Product Benchmarking
6.25.4 Strategic Initiatives
6.26 inVentiv Health Inc.
6.26.1 Company Overview
6.26.2 Financial Performance
6.26.3 Product Benchmarking
6.26.4 Strategic Initiatives
6.27 OptumInsight, Inc.
6.27.1 Company Overview
6.27.2 Financial Performance
6.27.3 Product Benchmarking
6.27.4 Strategic Initiatives
6.28 United BioSource Corporation
6.28.1 Company Overview
6.28.2 Financial Performance
6.28.3 Product Benchmarking
6.28.4 Strategic Initiatives
6.29 Ecron Acunova
6.29.1 Company Overview
6.29.2 Financial Performance
6.29.3 Product Benchmarking
6.29.4 Strategic Initiatives
6.30 Fortitude Clinical
6.30.1 Company Overview
6.30.2 Financial Performance
6.30.3 Product Benchmarking
6.30.4 Strategic Initiatives
6.31 ITClinical
6.31.1 Company Overview
6.31.2 Financial Performance
6.31.3 Product Benchmarking
6.31.4 Strategic Initiatives
Chapter 7. Methodology and Scope
7.1. Research Methodology
7.2. Research Scope & Assumption
7.3. List of Data Sources

List of Tables

1. Pharmacovigilance Market – Industry Summary & Critical Success Factors (CSFs)
2. Global Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020, Revenue (USD Million)
3. Global Pharmacovigilance Market Revenue, By Type of Service Provider , 2012 – 2020, Revenue (USD Million)
4. Global Pharmacovigilance Market Revenue, By Region, 2012 – 2020, Revenue (USD Million)
5. Pharmacovigilance Market – Key market driver analysis
6. Pharmacovigilance – Key market restraint analysis
7. North America Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
8. North America Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
9. North America Pharmacovigilance Market Revenue, By Type of Service provider, 2012 – 2020 (USD Million)
10. Europe Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
11. Europe Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
12. Europe Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
13. Asia Pacific Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
14. Asia Pacific Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
15. Asia Pacific Pharmacovigilance Market Revenue, By Type of service Provider, 2012 – 2020 (USD Million)
16. RoW Pharmacovigilance Market Size And Trends, 2012 – 2020, Revenue (USD Million)
17. RoW Pharmacovigilance Market Revenue, By Clinical Trial Phase, 2012 – 2020 (USD Million)
18. RoW Pharmacovigilance Market Revenue, By Type of Service Provider, 2012 – 2020 (USD Million)

List of Figures

1. Pharmacovigilance: Market Segmentation
2. Global Pharmacovigilance Market, 2012 – 2020, Revenue (USD Million)
3. Pharmacovigilance Market Dynamics
4. Key Opportunities Prioritized
5. Pharmacovigilance Market – Porter’s Analysis
6. Pharmacovigilance Market – PESTEL Analysis
7. Pharmacovigilance Company Market Share Analysis, 2013
8. Pharmacovigilance Market Share, By Clinical Trial Phase, 2013 & 2020
9. Pharmacovigilance Market Share, By Type of Service Provider, 2013 & 2020
10. Pharmacovigilance Market Share, By Region, 2013 & 2020



★調査レポート[医薬品の副作用調査の世界市場分析：臨床試験フェーズ別（前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験）、サービス提供者別（自宅内、契約委託）、セグメント予測、-2020] (コード：GVIEW707656)販売に関する免責事項を必ずご確認ください。
★調査レポート[医薬品の副作用調査の世界市場分析：臨床試験フェーズ別（前臨床試験、フェーズI / 1、フェーズII / 2、フェーズIII / 3、フェーズIV / 4試験）、サービス提供者別（自宅内、契約委託）、セグメント予測、-2020]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • eクリニカルソリューションの世界市場：製品別（eCOA、CTMS,、EDC、 CDMS）、提供方法別（ホームページ、認可企業、クラウドベース）、臨床試験フェーズ別、最終用途別、セグメント予測
    GVIEW805012 / Grand View Research / 2018年4月3日 / 本調査レポートでは、eクリニカルソリューションの世界市場について調査・分析し、eクリニカルソリューションの世界市場動向、eクリニカルソリューションの世界市場規模、市場予測、セグメント別eクリニカルソリューション市場分析、主要地域別市場規模、競争状況、関連企業情報などを含め、以下の構成でお届け致します。...The global eClinical solutions market size is expected to reach USD 12.0 billion by 2025, according to a new report by Grand View Research, Inc., registering a 13.6% CAGR during the forecast period. Increasing outsourcing and externalization of clinical trials by a majority of the prominent pharmaceutical and biotechnological companies is expected to drive the market at an unprecedented rate throughout the forecast period. Increasing research and development initiatives, rise in government grants to substantiate trials, and growing number of customers for eClinical solutions are also expected to boost the market during the forecast period. Drug development process is enhanced...

    • ◆H&Iグローバルリサーチのお客様（例）◆